Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal
Status:
Completed
Trial end date:
2019-02-28
Target enrollment:
Participant gender:
Summary
There is evidence in human studies as well as animal studies that treatments to lower
cholesterol can reduce the risk of dying from prostate cancer.To decide if
cholesterol-lowering therapy can slow the growth of prostate cancer, the investigators would
like to lower cholesterol prior to surgery and then measure the growth of prostate cancers
cells when the prostate has been removed. The investigators will use the combination of two
drugs that is approved by the U.S. Food and Drug Administration to lower cholesterol. The
drug combination is commercially available with a doctor's prescription and sold as Vytorin®.
It is known that maximal cholesterol-lower effects are seen after 2 weeks of treatment with
Vytorin®. Therefore, study patients receive at least 2 weeks, but no more than 6 weeks of
Vytorin® prior to surgery.
Phase:
Early Phase 1
Details
Lead Sponsor:
Cedars-Sinai Medical Center
Collaborator:
Roswell Park Cancer Institute
Treatments:
Ezetimibe Ezetimibe, Simvastatin Drug Combination Simvastatin